"Neurofilament Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Type III intermediate filament proteins that assemble into neurofilaments, the major cytoskeletal element in nerve axons and dendrites. They consist of three distinct polypeptides, the neurofilament triplet. Types I, II, and IV intermediate filament proteins form other cytoskeletal elements such as keratins and lamins. It appears that the metabolism of neurofilaments is disturbed in Alzheimer's disease, as indicated by the presence of neurofilament epitopes in the neurofibrillary tangles, as well as by the severe reduction of the expression of the gene for the light neurofilament subunit of the neurofilament triplet in brains of Alzheimer's patients. (Can J Neurol Sci 1990 Aug;17(3):302)
| Descriptor ID |
D016900
|
| MeSH Number(s) |
D05.750.078.593.630 D12.776.220.475.630 D12.776.631.630
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neurofilament Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neurofilament Proteins".
This graph shows the total number of publications written about "Neurofilament Proteins" by people in this website by year, and whether "Neurofilament Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 1 | 2 |
| 2024 | 2 | 1 | 3 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurofilament Proteins" by people in Profiles.
-
Prevalence, Severity, and Progression of Cerebellar Cognitive-Affective Syndrome in Patients With Spinocerebellar Ataxias. Neurology. 2025 Sep 09; 105(5):e213980.
-
Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination. Brain. 2025 Aug 01; 148(8):3011-3020.
-
ApoE e4-dependent Alteration of CXCR3?+?CD127+ CD4+ T cells associates with elevated plasma neurofilament light chain in Alzheimer's disease. J Alzheimers Dis. 2025 Apr; 104(3):792-807.
-
Distinct plasma lipids predict axonal injury and multiple sclerosis activity. J Neurol Neurosurg Psychiatry. 2025 Jan 16; 96(2):150-157.
-
Neurofilament light chain in serum of cancer patients with acute neurological complications. CNS Oncol. 2024 12 31; 13(1):2386233.
-
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nat Commun. 2024 May 20; 15(1):4297.
-
Temporal Profile of Serum Neurofilament Light (NF-L) and Heavy (pNF-H) Level Associations With 6-Month Cognitive Performance in Patients With Moderate-Severe Traumatic Brain Injury. J Head Trauma Rehabil. 2024 Nov-Dec 01; 39(6):E470-E480.
-
Parallel Cerebrospinal Fluid and Serum Temporal Profile Assessment of Axonal Injury Biomarkers Neurofilament-Light Chain and Phosphorylated Neurofilament-Heavy Chain: Associations With Patient Outcome in Moderate-Severe Traumatic Brain Injury. J Neurotrauma. 2024 07; 41(13-14):1609-1627.
-
Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Mult Scler. 2023 02; 29(2):206-211.
-
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).